These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21935911)

  • 1. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.
    Lowry KP; Lee JM; Kong CY; McMahon PM; Gilmore ME; Cott Chubiz JE; Pisano ED; Gatsonis C; Ryan PD; Ozanne EM; Gazelle GS
    Cancer; 2012 Apr; 118(8):2021-30. PubMed ID: 21935911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
    Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
    Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
    Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
    JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
    Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
    JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
    Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
    Phi XA; Saadatmand S; De Bock GH; Warner E; Sardanelli F; Leach MO; Riedl CC; Trop I; Hooning MJ; Mandel R; Santoro F; Kwan-Lim G; Helbich TH; Tilanus-Linthorst MM; van den Heuvel ER; Houssami N
    Br J Cancer; 2016 Mar; 114(6):631-7. PubMed ID: 26908327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
    Heijnsdijk EA; Warner E; Gilbert FJ; Tilanus-Linthorst MM; Evans G; Causer PA; Eeles RA; Kaas R; Draisma G; Ramsay EA; Warren RM; Hill KA; Hoogerbrugge N; Wasser MN; Bergers E; Oosterwijk JC; Hooning MJ; Rutgers EJ; Klijn JG; Plewes DB; Leach MO; de Koning HJ
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1458-68. PubMed ID: 22744338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
    Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
    BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
    de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
    Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in
    Guindalini RSC; Zheng Y; Abe H; Whitaker K; Yoshimatsu TF; Walsh T; Schacht D; Kulkarni K; Sheth D; Verp MS; Bradbury AR; Churpek J; Obeid E; Mueller J; Khramtsova G; Liu F; Raoul A; Cao H; Romero IL; Hong S; Livingston R; Jaskowiak N; Wang X; Debiasi M; Pritchard CC; King MC; Karczmar G; Newstead GM; Huo D; Olopade OI
    Clin Cancer Res; 2019 Mar; 25(6):1786-1794. PubMed ID: 30154229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
    Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
    Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.
    Le-Petross HT; Whitman GJ; Atchley DP; Yuan Y; Gutierrez-Barrera A; Hortobagyi GN; Litton JK; Arun BK
    Cancer; 2011 Sep; 117(17):3900-7. PubMed ID: 21365619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations.
    Hettipathirana T; Macdonald C; Xie J; Moodie K; Michael C; Phillips KA
    Med J Aust; 2021 Nov; 215(10):460-464. PubMed ID: 34420218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis.
    Phi XA; Houssami N; Obdeijn IM; Warner E; Sardanelli F; Leach MO; Riedl CC; Trop I; Tilanus-Linthorst MM; Mandel R; Santoro F; Kwan-Lim G; Helbich TH; de Koning HJ; Van den Heuvel ER; de Bock GH
    J Clin Oncol; 2015 Feb; 33(4):349-56. PubMed ID: 25534390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers.
    Berrington de Gonzalez A; Berg CD; Visvanathan K; Robson M
    J Natl Cancer Inst; 2009 Feb; 101(3):205-9. PubMed ID: 19176458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
    Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
    Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
    Obdeijn IM; Mann RM; Loo CCE; Lobbes M; Voormolen EMC; van Deurzen CHM; de Bock G; ; Hooning MJ
    Breast Cancer Res Treat; 2020 Jun; 181(3):581-588. PubMed ID: 32333294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
    Walsh EM; Farrell MP; Nolan C; Gallagher F; Clarke R; McCaffrey JA; Kennedy MJ; Barry M; Kell MR; Gallagher DJ
    Ir J Med Sci; 2016 Feb; 185(1):189-94. PubMed ID: 25673166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.